Passive immunization for immunocontraception: lessons learned from infectious diseases.

作者: Rajesh K Naz , Changanamkandath Rajesh , None

DOI: 10.2741/1407

关键词:

摘要: Development of vaccine for contraception is an exciting proposition that could provide a valuable alternative to the presently available methods birth control. Various targets such as gonadotropin releasing hormone (GnRH), follicle stimulating (FSH), leutinizing (LH), zona pellucida (ZP) antigens, sperm and human chorionic (hCG) are being explored immunocontraception. Besides specific concerns associated with each contraceptive vaccine, progress has been restricted by variability immune response after active immunization, attain maintain high antibody titers, time lag achieve reasonably good uncertainty regarding how long bioeffective antibodies will remain in circulation. It envisaged these may be taken care using preformed passive immunization approach. The therapies have tried found successful against various infectious diseases both animals well humans. Some become treatment modalities clinics. This manuscript review data polyclonal murine/humanized/human monoclonal antibodies, their efficacy, mode delivery, duration effects, limitations, if any. overall objective examine feasibility practicability approach

参考文章(57)
Flavio Vincenti, Robert Kirkman, Susan Light, Ginny Bumgardner, Mark Pescovitz, Philip Halloran, John Neylan, Alan Wilkinson, Henrik Ekberg, Robert Gaston, Lars Backman, James Burdick, Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation New England Journal of Medicine. ,vol. 338, pp. 161- 165 ,(1998) , 10.1056/NEJM199801153380304
Matthew E. Falagas, David R. Snydman, Richard Rohrer, Robin Ruthazer, John Griffith, Barbara G. Werner, Richard Freeman, Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clinical Transplantation. ,vol. 11, pp. 432- 437 ,(1997)
Mark Bodmer, Victoria A. Roberts, Alexander M. Collins, Cathy Martocello, Sally S. Varga, Linda K. Jolliffe, John R. Adair, Annette L. Rothermel, Robert A. Zivin, Virginia L. Pulito, Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. Journal of Immunology. ,vol. 156, pp. 2840- 2850 ,(1996)
E. Richard Stiehm, Standard and Special Human Immune Serum Globulins as Therapeutic Agents Pediatrics. ,vol. 63, pp. 301- 319 ,(1979)
Timothy W. Baba, Vladimir Liska, Regina Hofmann-Lehmann, Josef Vlasak, Weidong Xu, Seyoum Ayehunie, Lisa A. Cavacini, Marshall R. Posner, Hermann Katinger, Gabriela Stiegler, Bruce J. Bernacky, Tahir A. Rizvi, Russell Schmidt, Lori R. Hill, Michale E. Keeling, Yichen Lu, Joel E. Wright, Ting-Chao Chou, Ruth M. Ruprecht, Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection Nature Medicine. ,vol. 6, pp. 200- 206 ,(2000) , 10.1038/72309
D J Anderson, J Pudney, Immunobiology of the human penile urethra. American Journal of Pathology. ,vol. 147, pp. 155- 165 ,(1995)
Lionel S. Zuckier, Lorna D. Rodriguez, Matthew D. Scharff, Immunologic and Pharmacologic Concepts of Monoclonal Antibodies Seminars in Nuclear Medicine. ,vol. 19, pp. 166- 186 ,(1989) , 10.1016/S0001-2998(89)80012-1
Ravinder N. Maini, Ferdinand C. Breedveld, Joachim R. Kalden, Josef S. Smolen, Diana Davis, John D. MacFarlane, Christian Antoni, Burkhard Leeb, Michael J. Elliott, James N. Woody, Thomas F. Schaible, Marc Feldmann, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis & Rheumatism. ,vol. 41, pp. 1552- 1563 ,(1998) , 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W